Back to today’s briefing

Story perspectives

FDA Urges Higher Buprenorphine Doses to Combat Overdoses

1/18/2025

46 9

Summary

Story summary

The FDA is calling on manufacturers to revise labels for transmucosal buprenorphine products, allowing for higher doses in response to the increasing potency of opioids like fentanyl. Misleading dosage limits are obstructing effective treatment, but higher doses could significantly lower overdose deaths. The agency stresses the importance of personalized treatment and swift adjustments to optimal doses for those battling opioid use disorder.

1 of 1

Story summary

The FDA is calling on manufacturers to revise labels for transmucosal buprenorphine products, allowing for higher doses in response to the increasing potency of opioids like fentanyl. Misleading dosage limits are obstructing effective treatment, but higher doses could significantly lower overdose deaths. The agency stresses the importance of personalized treatment and swift adjustments to optimal doses for those battling opioid use disorder.